GO:0032535 regulation of cellular component size: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032535 regulation of cellular component size is a biological process that modulates the size of a cellular component, including organelles, membranes, and supramolecular structures.
• The Hippo signaling pathway is a master regulator of organ and cellular component size, controlling YAP/TAZ activity in response to cell contact and mechanical cues.
• Extracellular matrix components such as type V collagen and hyaluronan directly influence the size of scar tissue and pericellular matrices after injury.
• Dysregulation of cellular component size is linked to cancer, fibrosis, and metabolic disorders, making it a key area for therapeutic intervention.
• CRISPR-based knockout, knock-in, and overexpression models are essential for dissecting the genetic control of cellular component size.
• Advanced methods including imaging, proteomics, and CRISPR library screening enable systematic discovery of size-regulating genes and pathways.
Description
The Gene Ontology (GO) term GO:0032535, regulation of cellular component size, describes any biological process that modulates the size of a cellular component, such as an organelle, membrane, or extracellular matrix structure. This process is fundamental to cell physiology, tissue homeostasis, and organismal development, and its disruption contributes to diseases including cancer, fibrosis, and metabolic disorders. Understanding how cells control the dimensions of their components is therefore a central question in cell and developmental biology. The Hippo signaling pathway has emerged as a conserved regulator of organ size and cellular component size, acting through the YAP/TAZ transcriptional coactivators. In parallel, extracellular matrix remodeling by collagens and hyaluronan dynamically adjusts the size of pericellular and scar structures after injury. Researchers studying GO:0032535 employ a wide range of genetic, imaging, and biochemical tools to identify the genes and mechanisms that set and constrain the size of cellular components.
regulation of cellular component size At A Glance
| GO ID | GO:0032535 |
|---|---|
| GO term | regulation of cellular component size |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the size of cellular components, including organelles, membranes, and supramolecular structures |
| Key pathways | Hippo signaling, extracellular matrix remodeling, apoptotic regulation |
| Example genes | YAP1, WWTR1 (TAZ), COL5A1, HAS2, PXN |
| Disease relevance | Cancer, fibrosis, metabolic disorders, neuroimmune regulation |
| Research methods | CRISPR knockout/knock-in, imaging, proteomics, CRISPR library screening |
What Is GO:0032535?
According to the QuickGO definition, GO:0032535 regulation of cellular component size is a biological process that modulates the size of a cellular component. This includes any cellular component, such as an organelle, a membrane, a protein complex, or an extracellular matrix structure. The term encompasses both increases and decreases in size, and it is distinct from the regulation of cell size or organ size, although these processes are often coordinated.
Why Is regulation of cellular component size Important in Cell Biology?
Regulation of cellular component size is critical for normal development and tissue homeostasis, and its dysregulation is a hallmark of many diseases. The Hippo pathway controls organ size by inhibiting YAP/TAZ, and its inactivation leads to overgrowth and cancer. Extracellular matrix components such as type V collagen and hyaluronan regulate the size of scar tissue and pericellular matrices, influencing wound healing and fibrosis. Additionally, apoptotic regulation can exploit size control mechanisms in cancer. Thus, understanding GO:0032535 provides insights into fundamental biology and identifies therapeutic targets for a range of conditions.
• Controls organ size and tissue growth through the Hippo-YAP/TAZ pathway.
• Regulates scar size after heart injury via type V collagen.
• Modulates pericellular matrix size through hyaluronan metabolism.
• Influences cell contact inhibition and tissue growth control.
• Plays a role in monoclonal antibody production by cell line profiling.
• Involved in neuroimmune regulation of white adipose tissues.
• Exploited in apoptotic regulation in cancer.
• Paxillin interactions at focal adhesions affect cellular component size.
• Dysregulation leads to fibrosis, cancer, and metabolic disorders.
• Provides targets for CRISPR-based functional screens and drug discovery.
What Happens During regulation of cellular component size?
Hippo pathway signaling
In simple terms: The Hippo pathway acts like a brake on organ growth by controlling the size of cells and tissues.
The Hippo pathway is a kinase cascade that phosphorylates and inactivates the transcriptional coactivators YAP and TAZ, thereby restricting organ size. When the pathway is off, YAP/TAZ enter the nucleus and drive expression of genes that promote cell proliferation and survival, leading to increased cellular component size. Cell contact inhibition activates the Hippo pathway, ensuring that tissues stop growing when they reach the appropriate size.
Extracellular matrix remodeling
In simple terms: The matrix around cells can expand or shrink, changing the size of structures like scars.
Type V collagen in scar tissue regulates the size of scar after heart injury by influencing collagen fibril assembly and matrix stiffness. Hyaluronan, a glycosaminoglycan, modulates pericellular matrix size through its synthesis and degradation, affecting cell migration and proliferation. These matrix components provide mechanical cues that feed back on cellular component size regulation.
Apoptotic regulation
In simple terms: Programmed cell death can shrink cellular components as part of normal turnover.
Apoptotic regulation is exploited in cancer to control cell number and size. During apoptosis, cellular components such as the nucleus and mitochondria undergo size changes, and this process is tightly regulated. Dysregulation of apoptosis can lead to uncontrolled growth or atrophy of cellular components.
Focal adhesion and cytoskeletal dynamics
In simple terms: The cell's internal skeleton and attachment points help determine the size of cellular structures.
Paxillin interactions at focal adhesions link the extracellular matrix to the actin cytoskeleton, influencing cell shape and the size of adhesion complexes. These dynamic structures are regulated during cell migration and tissue remodeling, contributing to the overall size of cellular components.
Key Genes Involved in GO:0032535 regulation of cellular component size
The following genes and proteins are key regulators of cellular component size, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| YAP1 | Transcriptional coactivator that promotes organ growth; inhibited by Hippo pathway | Knockout reduces organ size; overexpression causes overgrowth |
| WWTR1 (TAZ) | Paralog of YAP; regulates mesenchymal differentiation and size | Knockout affects tissue homeostasis |
| COL5A1 | Type V collagen; regulates scar size after heart injury | Knockout alters collagen fibril diameter |
| HAS2 | Hyaluronan synthase 2; synthesizes hyaluronan to modulate matrix size | Knockout reduces pericellular matrix |
| PXN | Paxillin; focal adhesion protein affecting cytoskeletal size | Knockdown alters adhesion complex size |
| STK3/4 | Hippo kinases Mst1/2; phosphorylate LATS1/2 | Knockout activates YAP and increases organ size |
| LATS1/2 | Hippo kinases that phosphorylate YAP/TAZ | Knockout leads to YAP activation and overgrowth |
| NF2 | Merlin; upstream activator of Hippo pathway | Mutation causes neurofibromatosis and overgrowth |
| WWC1 | KIBRA; upstream regulator of Hippo pathway | Knockout affects organ size |
| AMOT | Angiomotin; regulates YAP/TAZ localization | Knockdown changes cell size |
| TEAD1-4 | Transcription factors that bind YAP/TAZ | Knockout blocks YAP-driven growth |
| CTGF (CCN2) | YAP target gene; promotes matrix remodeling | Overexpression increases matrix size |
| CYR61 (CCN1) | YAP target gene; regulates cell adhesion | Knockdown reduces proliferation |
| BIRC5 | Survivin; apoptosis inhibitor | Overexpression increases cell survival |
| BAX | Pro-apoptotic factor | Knockout reduces apoptosis and increases size |
| BCL2 | Anti-apoptotic factor | Overexpression blocks apoptosis |
| CASP3 | Executioner caspase | Knockout affects apoptotic size changes |
How Is regulation of cellular component size Regulated?
Regulation of cellular component size is controlled by multiple signaling pathways. The Hippo pathway is a central regulator, where upstream signals such as cell density, mechanical stress, and G-protein-coupled receptor signaling modulate the kinase cascade that inactivates YAP/TAZ. Extracellular matrix stiffness and composition, including type V collagen and hyaluronan, provide mechanical and biochemical cues that feed back on size regulation. Additionally, apoptotic regulators such as BCL2 family proteins control the size of cellular components during cell death. Neuroimmune signals also influence adipose tissue size.
regulation of cellular component size and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| YAP1 | Cancer, organ overgrowth | Knockout and overexpression in cancer cell lines |
| COL5A1 | Cardiac fibrosis, scar formation | Knockout mice and cardiac injury models |
| HAS2 | Fibrosis, inflammation | Knockout and knock-in in fibroblast lines |
| PXN | Cancer metastasis, cell migration | Point mutation at focal adhesion sites |
| BCL2 | Lymphoma, apoptosis resistance | Overexpression in hematopoietic cells |
Cancer
Dysregulation of cellular component size is a hallmark of cancer. Inactivation of the Hippo pathway leads to YAP/TAZ activation, driving uncontrolled proliferation and organ overgrowth. Apoptotic regulation is exploited in cancer, where overexpression of anti-apoptotic proteins like BCL2 increases cell survival and tumor size. Targeting these pathways is a promising therapeutic strategy.
Fibrosis and scar formation
Type V collagen in scar tissue regulates the size of scar after heart injury, and its dysregulation can lead to excessive fibrosis. Hyaluronan metabolism also affects pericellular matrix size and is implicated in fibrotic diseases. Modulating these components could reduce scar size and improve tissue repair.
Metabolic disorders
Neuroimmune regulation of white adipose tissues involves changes in adipocyte size and number. Dysregulation of these processes contributes to obesity and insulin resistance. Understanding the size control mechanisms in adipose tissue may reveal new therapeutic targets.
From regulation of cellular component size-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does YAP1 knockout reduce organ size? | YAP1 knockout mouse model or cell line |
| How does COL5A1 mutation affect scar size? | Col5a1 knock-in mouse with point mutation |
| What is the role of HAS2 in pericellular matrix size? | HAS2 overexpression and knockout in fibroblasts |
| Can CRISPR screen identify new size regulators? | Genome-wide CRISPR knockout library in HeLa cells |
| How does paxillin phosphorylation affect adhesion size? | PXN point mutation knock-in cell lines |
| Does BCL2 overexpression increase cell size? | BCL2 overexpression in cancer cell lines |
How to Study the regulation of cellular component size Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Confocal microscopy | Size of organelles and matrix structures | Quantifying scar size after heart injury |
| High-content imaging | Cell and component size | Screening for size regulators |
| CRISPR knockout library | Gene essentiality for size control | Genome-wide screens |
| RNA-seq | Transcriptional changes | Identifying YAP target genes |
| Proteomics | Protein composition of components | Analyzing focal adhesions |
| Western blot | Protein expression and phosphorylation | Hippo pathway activity |
| Flow cytometry | Cell size and granularity | Adipocyte size analysis |
| Immunohistochemistry | Tissue architecture and component size | Scar tissue analysis |
Imaging-based size quantification
High-content imaging and confocal microscopy allow direct measurement of cellular component size, including organelle dimensions and matrix thickness. Fluorescent labeling of specific components enables quantitative analysis across thousands of cells.
CRISPR library screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate cellular component size. Cells are sorted based on size or imaged, and sgRNA enrichment is analyzed by next-generation sequencing.
Proteomics and interactomics
Mass spectrometry-based proteomics can reveal changes in protein composition of cellular components upon size regulation. Affinity purification of size-regulating complexes identifies interaction partners.
Transcriptomics and bioinformatics
RNA-seq and single-cell transcriptomics combined with bioinformatics can uncover gene expression programs that drive size changes. Pathway enrichment analysis links candidate genes to GO:0032535.
How CRISPR Can Be Used to Study GO:0032535 regulation of cellular component size
Knockout
CRISPR knockout of genes such as YAP1, COL5A1, or HAS2 allows researchers to determine their causal role in regulating cellular component size. For example, YAP1 knockout reduces organ size and cell proliferation.
Point Mutation
Introducing point mutations in genes like PXN or LATS1 can dissect specific phosphorylation sites or domains required for size regulation. This provides mechanistic insights beyond simple knockout.
Knock-in
Knock-in of tagged versions of proteins such as YAP1 or COL5A1 enables live-cell imaging and proteomic analysis of size-regulating complexes. This helps track dynamic changes in cellular component size.
Overexpression
Overexpression of YAP1, BCL2, or HAS2 can drive increases in cellular component size and model disease states such as cancer and fibrosis.
How EDITGENE Supports regulation of cellular component size Research
Researchers studying regulation of cellular component size-related genes often need to determine whether a candidate gene is causally involved in size control or merely correlated with it. This requires precise genetic manipulation, which is where EDITGENE's CRISPR services can accelerate discovery.
Contact EDITGENE today to design your custom CRISPR model for regulation of cellular component size research.
Frequently Asked Questions About regulation of cellular component size
What is GO:0032535 regulation of cellular component size?
GO:0032535 is a Gene Ontology biological process term that describes any process that modulates the size of a cellular component, such as an organelle, membrane, or extracellular matrix structure.
What genes are involved in regulation of cellular component size?
Key genes include YAP1, WWTR1 (TAZ), COL5A1, HAS2, PXN, STK3/4, LATS1/2, NF2, and BCL2, among others.
How does the Hippo pathway regulate cellular component size?
The Hippo pathway phosphorylates and inactivates YAP/TAZ, preventing their nuclear entry and thereby restricting organ and cellular component size.
What diseases are associated with dysregulation of cellular component size?
Cancer, fibrosis, scar formation, and metabolic disorders such as obesity are linked to dysregulation of cellular component size.
What methods are used to study regulation of cellular component size?
Common methods include confocal imaging, CRISPR library screening, RNA-seq, proteomics, and flow cytometry.
Can CRISPR be used to study regulation of cellular component size?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in size regulation.
What is the role of type V collagen in scar size?
Type V collagen in scar tissue regulates the size of scar after heart injury by influencing collagen fibril assembly and matrix stiffness.
How does hyaluronan affect cellular component size?
Hyaluronan modulates pericellular matrix size through its synthesis and degradation, affecting cell migration and proliferation.
What is the role of apoptosis in cellular component size?
Apoptotic regulation can shrink cellular components as part of normal turnover, and its dysregulation is exploited in cancer.
How can I model regulation of cellular component size in the lab?
You can use CRISPR knockout, knock-in, or overexpression cell lines, combined with imaging and screening methods, to model size regulation.
Conclusion
GO:0032535 regulation of cellular component size is a fundamental biological process with broad implications for development, homeostasis, and disease. The Hippo pathway, extracellular matrix components, and apoptotic regulators are key players, and their dysregulation contributes to cancer, fibrosis, and metabolic disorders. Advances in CRISPR-based models and high-throughput screening are accelerating the discovery of new size-regulating genes and mechanisms. EDITGENE's comprehensive services support researchers in dissecting this process with precision and scale.
References
- 1. Guo P et al.. 2025. The Hippo pathway: Organ size control and beyond.. Pharmacol Rev 77(2):100031 PMID: 40148032
- 2. Yokota T et al.. 2020. Type V Collagen in Scar Tissue Regulates the Size of Scar after Heart Injury.. Cell 182(3):545-562.e23 PMID: 32621799
- 3. Zhao B et al.. 2007. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.. Genes Dev 21(21):2747-61 PMID: 17974916
- 4. Kang S et al.. 2014. Cell line profiling to improve monoclonal antibody production.. Biotechnol Bioeng 111(4):748-60 PMID: 24249214
- 5. Kobayashi T et al.. 2020. Hyaluronan: Metabolism and Function.. Biomolecules 10(11) PMID: 33171800
- 6. Turner CE. 2000. Paxillin interactions.. J Cell Sci 113 Pt 23:4139-40 PMID: 11069756
- 7. Qian X et al.. 2022. Neuroimmune regulation of white adipose tissues.. FEBS J 289(24):7830-7853 PMID: 34564950
- 8. Ucker DS et al.. 2018. Exploitation of Apoptotic Regulation in Cancer.. Front Immunol 9:241 PMID: 29535707
